Please login to the form below
Focus on multiple myeloma treatment: Witnessing a transformation
Consultant David Cooney of Blue Latitude Health will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.
I get very excited by science,
specifically pharmacology, and when I was studying drug development I used to
read case studies about the impact ground-breaking drugs had, and imagine what
it must have been like to be part of that success. I used to harass an old mentor
of mine who was involved in the Herceptin launch for stories about introducing
such an innovative treatment, hoping one day I’d get a chance to be part of such
a transformation in care.
I'm now part of a team at Blue Latitude Health working in multiple myeloma (MM), and with each publication that emerges, it’s clear that we are witnessing a transformation in the treatment of multiple myeloma. In this article, I will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.
If we reflect on what the treatment options were 10 years ago, two drugs stand out – melphalan and thalidomide. Melphalan, a distant cousin of the mustard gas used to kill World War I soldiers, and thalidomide, the infamous chiral drug which caused birth defects in the 1960s. These drugs have been shown to be efficacious options for patients with MM, but with a low therapeutic index. This meant significant cost in terms of toxicity, and marginal impact on the overall survival of patients.
![]()
I'm now part of a team at Blue Latitude Health working in multiple myeloma (MM), and with each publication that emerges, it’s clear that we are witnessing a transformation in the treatment of multiple myeloma. In this article, I will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.
The Therapeutic Index of multiple myeloma therapies
“It is easy to be overwhelmed by hype in cancer research, with promising new discoveries often portrayed as so-called game changers….but myeloma is a rare exception” [sic] was the opening of a recent editorial in the Lancet on multiple myeloma. To appreciate the context of this statement we need to consider what treatment options were like for myeloma patients in the past.If we reflect on what the treatment options were 10 years ago, two drugs stand out – melphalan and thalidomide. Melphalan, a distant cousin of the mustard gas used to kill World War I soldiers, and thalidomide, the infamous chiral drug which caused birth defects in the 1960s. These drugs have been shown to be efficacious options for patients with MM, but with a low therapeutic index. This meant significant cost in terms of toxicity, and marginal impact on the overall survival of patients.
Download the full article from Blue Latitude Health
Company Details
Blue Latitude Health
+44 203 328 1840
Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom
Latest content on this profile
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
- Unpacking rare diseases in the first edition of Delta magazine
- Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health
- Great creative is effective creative. And effective creative is affective creative
- Our creative approach at Fishawack Health is Affective Creativity. Creative crafted to make deep, motivating connections with our target audience. We tap into psychology and combine that with creative craft and expertise and to deliver powerful, engaging work on a conscious as well as a subconscious level.
Blue Latitude Health
- How to make an impact at a virtual congress
- As hard as congress organisers try, replicating the congress experience on a virtual platform is difficult. Rather than trying to replicate the in-person congress experience, the industry has a real opportunity to innovate, leverage the benefits of digital channels, and approach congresses in a completely different way.
Blue Latitude Health
